7-溴-萘-2-基-甲醇 | 627527-19-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 7-溴-萘-2-基-甲醇
• 英文名称: (7-bromonaphthalen-2-yl)methanol
• 英文别名: 2-Naphthalenemethanol, 7-bromo-
• CAS: 627527-19-9
• 化学式: C₁₁H₉BrO
• 分子量: 237.096
• InChiKey: YLFSBYGBYCQPIN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  7-溴-萘-2-基-甲醇 在 氯化亚砜 、 zinc(II) chloride 作用下， 以 1,4-二氧六环 、 水 、 乙腈 为溶剂， 反应 19.67h， 生成 (7-Bromo-naphthalen-2-yl)-acetonitrile
  参考文献：
  名称：

  Antihyperglycemic activity of novel naphthalenylmethyl-3H-1,2,3,5-oxathiadiazole 2-oxides

  摘要：

  A series of naphthalenyl 3H-1,2,3,5-oxathiadiazole 2-oxides was prepared and tested for antihyperglycemic activity in the db/db mouse, a model for type 2 (non-insulin dependent) diabetes mellitus. Substitution at the 1-, 5-, or 8-positions of the naphthalene ring with a halogen was found to be beneficial to antihyperglycemic activity. 4-[(5-Chloronaphthalen-2-yl)methyl]-3H-1,2,3,5-oxathiadiazole 2-oxide (45), one of the most potent compounds in this series, was selected for further pharmacological evaluation.

  DOI：

  10.1021/jm00069a006
• 作为产物：
  描述：

  2,7-二溴萘 在 甲醇 、 sodium tetrahydroborate 、 正丁基锂 作用下， 以 四氢呋喃 为溶剂， 反应 4.5h， 生成 7-溴-萘-2-基-甲醇
  参考文献：
  名称：

  使用π扩展亲电试剂的无环酯的对映选择性α-苄基化

  摘要：

  报道了无环酯的第一次不对称协作路易斯碱/钯催化的苄基烷基化。该反应通过立体定义的C1-烯醇铵盐亲核试剂进行。成功的关键是鉴定具有独特反应性的磷酸苄基亲电试剂。获得的烷基化产物具有很高的对映选择性，该方法已应用于凝血酶抑制剂DX‐9065a的合成。

  DOI：

  10.1002/anie.201806742

文献信息

• Substituted imidazol-pyridazine derivatives
  申请人：——

  公开号：US20030229096A1

  公开（公告）日：2003-12-11

  The present invention relates to compounds of formula 1 wherein A is an unsubstituted or substituted cyclic group; and R is hydrogen or lower alkyl; or a pharmaceutically acceptable acid addition salt thereof. These compounds are NMDA NR-2B receptor subtype specific blockers and are useful in the treatment of neurodegeneration, depression and pain.

  本发明涉及以下式的化合物 1 其中A是未取代或取代的环状基团；以及 R是氢或较低的烷基； 或其药学上可接受的酸盐。这些化合物是NMDA NR-2B受体亚型特异性阻断剂，对于治疗神经退行性疾病、抑郁症和疼痛具有用处。
• (IMIDAZOL-1-YL-METHYL)-PYRIDAZINE AS NMDA RECEPTOR BLOCKER
  申请人：F. Hoffmann-La Roche AG

  公开号：EP1506190A1

  公开（公告）日：2005-02-16
• US7005432B2
  申请人：——

  公开号：US7005432B2

  公开（公告）日：2006-02-28
• [EN] (IMIDAZOL-1-YL-METHYL)-PYRIDAZINE AS NMDA RECEPTOR BLOCKER<br/>[FR] (IMIDAZOL-1-YL-METHYL)-PYRIDAZINE EN TANT QU'ANTAGONISTE DU RECEPTEUR NMDA
  申请人：HOFFMANN LA ROCHE

  公开号：WO2003097637A1

  公开（公告）日：2003-11-27

  The present invention relates to compounds of formula (I) wherein A is an unsubstituted cyclic group; and R is hydrogen or lower alkyl; and pharmaceutically acceptable acid addition salts thereof. It has been shown that the compounds of formulas IA and IB are good NMDA NR-2B receptor subtype specific blockers. Possible therapeutic indications for these compounds include acute forms of neurodegeneration caused, e.g., by stroke and brain trauma, and chronic forms of neurodegeneration such as Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS(amyotrophic lateral sclerosis) and neurodegeneration associated with bacterial or viral infections and, in addition, depression and chronic and acute pain.
• [EN] 6-OXODECAHYDROPYRROLO[1,2-A][1,5]DIAZOCINE AND 6-OXODECAHYDRO-4H-PYRROLO[2,1-D][1,5]THIAZOCINE DERIVATIVES AS STAT3 AND STAT6 MODULATORS FOR THE TREATMENT OF CANCER AND INFLAMMATORY CONDITIONS<br/>[FR] DÉRIVÉS DE 6-OXODÉCAHYDROPYRROLO [1,2-A] [1,5] DIAZOCINE ET DE 6-OXODÉCAHYDRO-4 H-PYRROLO [2,1-D] [1,5] THIAZOCINE EN TANT QUE MODULATEURS STAT3 ET STAT6 POUR LE TRAITEMENT DU CANCER ET D'ÉTATS INFLAMMATOIRES
  申请人：[en]RECLUDIX PHARMA, INC.

  公开号：WO2023164680A1

  公开（公告）日：2023-08-31

  Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with STAT3 and/or STAT6, such as e.g. cancer and inflammatory conditions. Preferred compounds are 6-oxodecahydropyrrolo[1,2-a][1,5]diazocine and 6-oxodecahydro-4H-pyrrolo[2,1-d][1,5]thiazocine derivatives.